New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:49 EDTEXELExelixis price target lowered to $9 from $11 at Stifel
Stifel cut its price target on Exelixis after the company announced that a committee had determined that its Phase III trial should continue based on lack of sufficient survival benefit to halt the trial,. The firm had expected the trial to be stopped early due to efficacy. Stifel notes that trials of competing drugs have been stopped early due to favorable results. However, it thinks the final results of Exelixis' trial could still be positive and keeps a Buy rating on the shares.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
05:24 EDTEXELExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 11, 2014
07:28 EDTEXELCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use